Literature DB >> 10407819

Pulmonary veno-occlusive disease, antiphospholipid antibody and pulmonary hypertension in an adolescent.

A Hussein1, E Trowitzsch, M Brockmann.   

Abstract

UNLABELLED: Pulmonary veno-occlusive disease (PVOD) is a rare cause of pulmonary hypertension (PH); Antiphospholipid antibody (APL) is another known cause of pulmonary hypertension, due to recurrent pulmonary thromboembolism. The coincidence of both causes, PVOD and APL, without thromboembolism, in PH has not been reported previously in children. A 12.5-year-old boy presented with a one year history of fatigue. Pulmonary hypertension was diagnosed by echocardiography. Pulmonary function tests revealed a moderate restrictive pattern and elevated granulocytes were detected in bronchoalveolar lavage. An isolated high-titer APL was detected. Open lung biopsy established the diagnosis of PVOD, with no evidence of pulmonary thrombosis, but with accompanying interstitial and alveolar cellular infiltration. We speculate that APL may have played a role in the pathogenesis of PVOD. Prednisone++ improved the symptoms of the interstitial pneumonitis and was stopped; on follow up of 30 months, the patient ist in stable condition on therapy with nifedipin, phenprocoumon and digoxin.
CONCLUSIONS: PVOD and APL may be present simultaneously as a rare cause of PH. Interstitial pneumonitis may accompany PVOD and produce the leading symptoms. Open lung biopsy is essential for early establishment of the diagnosis.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10407819     DOI: 10.1055/s-2008-1043773

Source DB:  PubMed          Journal:  Klin Padiatr        ISSN: 0300-8630            Impact factor:   1.349


  2 in total

Review 1.  Pulmonary hypertension associated with antiphospholipid antibody: Call for a screening tool?

Authors:  Rukma Parthvi; Rutuja R Sikachi; Abhinav Agrawal; Ajay Adial; Abhinav Vulisha; Sameer Khanijo; Arunabh Talwar
Journal:  Intractable Rare Dis Res       Date:  2017-08

Review 2.  The lung in the antiphospholipid syndrome.

Authors:  G Espinosa; R Cervera; J Font; R A Asherson
Journal:  Ann Rheum Dis       Date:  2002-03       Impact factor: 19.103

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.